More study needed on GSK flu shot says WHO
London, February 8, 2011
The World Health Organisation (WHO) said more investigation was needed into the possible risk of narcolepsy, a rare sleeping disorder, from GlaxoSmithKline's Pandemrix H1N1 flu vaccine.
A WHO advisory panel made the decision after a Finnish study published last week suggested children who got the shot were nine times more likely to suffer from narcolepsy, which causes a person to fall asleep suddenly and unexpectedly.
WHO spokeswoman Alison Brunier told a briefing in Geneva that Pandemrix remains on the WHO's list of prequalified vaccines, and there would be no changes to WHO recommendations as a result of the Finnish study.
"This means that countries should continue vaccinating against H1N1 to immunise people at risk of severe disease ...using monovalent vaccines, including Pandemrix, if no trivalent seasonal vaccine is available," she said.
A spokesman for the British drugmaker said it had been expecting the WHO statement and was itself looking into reports of links between narcolepsy and Pandemrix.
"GSK is reviewing the Finnish report and believes it would be premature to draw any conclusions," he said in a statement.
Pandemrix was designed to tackle the H1N1 pandemic flu which spread around the world in 2009 and 2010.
It is not currently being widely used, as the pandemic was declared over in August last year, but doctors in some countries, such as Britain, have been advised to use it if their stocks of seasonal flu vaccines run low.
The United Nations health body said an increased risk of narcolepsy had not been seen in association with the use of any other vaccines, either against flu or other diseases.
"At this stage, it does not appear that narcolepsy following vaccination against pandemic influenza is a general worldwide phenomenon and this complicates interpretation of the findings in Finland," the WHO's advisory panel said in a statement.
It said the Stockholm-based European Centre for Disease Prevention and Control (ECDC), which monitors disease in the European Union (EU), is currently conducting studies of narcolepsy and pandemic flu vaccines. -Reuters
More Health & Environment Stories
- Obesity rate at 72pc among Saudi adults
- Bahrain ideal for artificial rain experiment
- Riyadh 'among most polluted cities'
- CGM acquires 3 European healthcare IT providers
- The age of genomic medicine dawns, finally
- Over 300 exhibitors for Saudi healthcare event
- Mackeen unveils document management solution
- Seha opens new clinics in Abu Dhabi, Al Ain
- SARS virus claims one more victim in Saudi
- New support group comes to overeaters' rescue
- RAK Hospital launches urinary clinic for women
- NBAD backs Emiratis on Antarctica trip
- Cut sugar intake drastically urges WHO
- Al khaliji to fund Qatar recycling plant
- Qatar researcher in 360km breast cancer run
- New facilitator to open in DHCC
- Many countries lack capacity to prevent hearing loss
- QUIT NOW: Passive smoking hurts kids' arteries
- San Francisco to ban plastic water bottles
- GSK wins home toothpaste award for Sensodyne
- E-integration vital to GCC healthcare industry
- Fakih IVF unveils two new genetic tests
- 2 die from H1N1 in Oman
- Al Noor Hospitals targets domestic growth
- Medical panel on the way in Bahrain
- 40pc of UAE adults ‘have hypertension’
- Saudi diabetics urged to stay away from camels
- GCC readies plan to fight heart diseases
- Bahrain opens sickle cell hospital
- Hazardous waste focus for Oman summit